Cisen Pharmaceutical Co., Ltd. (SHA:603367)

Market Cap	6.85B +10.5%
Revenue (ttm)	3.44B -13.5%
Net Income	421.25M -17.2%
EPS	0.93 -17.0%
Shares Out	452.75M
PE Ratio	16.28
Forward PE	n/a
Dividend	0.32 (2.08%)
Ex-Dividend Date	n/a

Volume	9,653,284
Average Volume	11,345,450
Open	15.48
Previous Close	15.14
Day's Range	15.42 - 15.79
52-Week Range	13.25 - 35.20
Beta	0.33
RSI	43.91
Earnings Date	Apr 3, 2026

About Cisen Pharmaceutical

Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company’s chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and analgesic drugs, obstetrics and gynecology medication, digestive system medication, respiratory system medication, immune system drugs, and hormonal dru...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 3,114
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603367

Financial Performance

In 2025, Cisen Pharmaceutical's revenue was 3.44 billion, a decrease of -13.48% compared to the previous year's 3.98 billion. Earnings were 421.25 million, a decrease of -17.22%.